Pascual M, Schifferli J A
Laboratoire d'immunonéphrologie, Centre médical universitaire, Genève.
Schweiz Med Wochenschr. 1993 Jan 23;123(3):39-43.
Immune complexes (IC), after reacting with the complement system, bear C3b fragments (opsonized IC) and bind to the CR1 receptor that is present on human erythrocytes (CR1 = complement receptor type 1). This efficient binding reaction prevents random vascular IC deposition, and allows IC to be transported through the circulation to the fixed macrophage system of the liver and spleen, where they are safely eliminated. The structure of CR1, with multiple C3b binding sites, and the clustered distribution of CR1 on the erythrocyte surface favor the multivalent binding of opsonized IC to erythrocytes. CR1 on erythrocytes serves as a cofactor for the inactivation of C3b by factor I, thus allowing the release of IC from the erythrocyte surface and their transfer to fixed macrophages. Under normal circumstances, the erythrocyte plays a major role in the processing of IC in humans.
免疫复合物（IC）与补体系统反应后，带有C3b片段（调理素化IC），并与存在于人类红细胞上的CR1受体（CR1 = 1型补体受体）结合。这种高效的结合反应可防止IC在血管中随机沉积，并使IC通过循环系统运输到肝脏和脾脏的固定巨噬细胞系统，在那里它们被安全清除。CR1具有多个C3b结合位点，其在红细胞表面的聚集分布有利于调理素化IC与红细胞的多价结合。红细胞上的CR1作为I因子使C3b失活的辅因子，从而使IC从红细胞表面释放并转移到固定巨噬细胞。在正常情况下，红细胞在人类IC的处理中起主要作用。
